[صفحه اصلی ]   [Archive] [ English ]  
:: جلد 21، شماره 2 - ( مجله چشم پزشكي ايران 1388 ) ::
جلد 21 شماره 2 صفحات 13-18 برگشت به فهرست نسخه ها
Central Retinal Artery Perfusion following 0.1 ml Intravitreal Injection of Bevacizumab
دكتر حسین نظری*، دكتر مهدی مدرس زاده، دكتر محسن بهمنی کشکولی، دكتر مسعود ناصری پور، دكتر محمدمهدی پرورش، پریدخت نظری
، h01nazari@yahoo.com
چکیده:   (20418 مشاهده)

Purpose: To study the pattern of perfusion of central retinal artery (CRA) after 0.1 ml intravitreal injection of bevacizumab to verify the need for any maneuver to decrease the intraocular pressure (IOP) including anterior chamber paracentesis (ACP)

Methods: This is a prospective, interventional, noncomparative case series. Patients receiving intravitreal injection of bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration, diabetic macular edema and retinal veno-occlusive diseases were included in the study. Each eye received 0.1 ml intravitreal injection of bevacizumab and the status of perfusion of CRA and its pulsation was monitored by indirect ophthalmoscopy until cessation of visible pulsation. Main outcome measures were patency of CRA, its pulsation and time from injection to cessation of pulsation.

Results: Seventy seven eyes of 70 patients were studied. At first ophthalmoscopy 30 seconds after injection, CRA was open in all cases with or without pulsation. CRA occlusion was not observed in any case. In 20 eyes (26%) CRA was patent without pulsation. In 57 eyes (74%) CRA pulsation was detected and this visible pulsation of CRA stopped within an average time of 167±99 seconds (range: 30-480 seconds). From 17 eyes which had significant vitreous reflux, only 6 eyes had CRA pulsation which stopped in a mean time of 80±36 seconds. There was a significant difference between pulsation duration in patients with and without vitreous reflux (Mann-Whitney U test, P=0.005). Absence of postinjection vitreous reflux was a risk factor for CRA pulsation after intravitreal injection of 0.1 ml of bevacizumab (relative risk: 2.41, 95% CI: 1.25-4.62).

Conclusion: Considering the absence of CRA closure and the short time needed for the cessation of pulsation after intravitreal injection of 0.1 ml bevacizumab, no treatment including ACP is warranted before or after such injections in nonglaucomatous eyes. Indirect ophthalmoscopy is a noninvasive useful maneuver to ascertain patency of CRA after intravitreal injections.

  

Iranian Journal of Ophthalmology 200921(2):13-18 © 2009 by the Iranian Society of Ophthalmology
متن کامل [PDF 63 kb]   (3955 دریافت)    
نوع مطالعه: پژوهشی | موضوع مقاله: عمومى
ارسال پیام به نویسنده مسئول

ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

CAPTCHA


XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nazari H, ModarresZadeh M, Bahmani-Kashkouli M, Naseripour M, Parvaresh M, Nazari P. Central Retinal Artery Perfusion following 0.1 ml Intravitreal Injection of Bevacizumab. Iranian Journal of Ophthalmology. 2009; 21 (2) :13-18
URL: http://irjo.org/article-1-226-fa.html

نظری حسین، مدرس زاده مهدی، بهمنی کشکولی محسن، ناصری پور مسعود، پرورش محمدمهدی، نظری پریدخت. Central Retinal Artery Perfusion following 0.1 ml Intravitreal Injection of Bevacizumab. مجله چشم پزشکی ایران. 1388; 21 (2) :13-18

URL: http://irjo.org/article-1-226-fa.html



جلد 21، شماره 2 - ( مجله چشم پزشكي ايران 1388 ) برگشت به فهرست نسخه ها
مجله چشم پزشکی ایران Iranian Journal of Ophthalmology
Persian site map - English site map - Created in 0.06 seconds with 31 queries by YEKTAWEB 4006